Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

The Effect of Stimulating Substances on Brain Activity of Preterm Infants

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Christine Czaba, Medical University of Vienna Identifier:
First received: April 27, 2011
Last updated: October 30, 2015
Last verified: October 2015

Introduction: Methylxanthines and doxapram have been widely used for the treatment of apneas of prematurity. Both substances have effects on the central nervous system. While there are data available concerning the use of caffeine (the methylxanthine used at our NICU) even proposing a positive effect on neurodevelopmental outcome of very preterm infants, there are data which suggest a negative effect of the central stimulants doxapram on longterm outcome in this group of infants. Nevertheless concerning both medications only few studies have been published and only scarce data are available concerning the effect of these medications on brain activity of very preterm infants until now.

The aim of this study: is the assessment of the effect of stimulating substances on brain activity of preterm infants born below 30 weeks of gestation and their longterm neurodevelopmental follow-up.

Methods: This study is a prospective study including preterm infants born below 30 weeks of gestational age. Brain activity is measured by one-channel amplitude-integrated EEG (aEEG). The first aEEG measurement is performed without caffeine and/or doxapram medication. At least one hour of brain activity is registrated. The second measurement is done at least 24 hours after the start of caffeine and/ or doxapram treatment.

The percentage of different background patterns, the occurrence and duration of sleep-wake-cycling, and the occurrence and duration of seizures is assessed and analysed. Neurodevelopmental outcome is assessed at one and two years of corrected age by assessment of the Bayley Scales of Infant Development II and standardized clinical neurological examination.

Apneas of Prematurity

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: The Effect of Stimulating Substances on Brain Activity Measured by Amplitude-integrated EEG and Long-term Neurodevelopmental Outcome of Preterm Infants Born Below 30 Weeks of Gestation

Resource links provided by NLM:

Further study details as provided by Medical University of Vienna:

Estimated Enrollment: 60
Study Start Date: June 2009
Estimated Study Completion Date: June 2016
Primary Completion Date: November 2010 (Final data collection date for primary outcome measure)
Caffeine group
Premature infants below 30 weeks of gestation who receive Caffeine treatment
Caffeine and Doxapram group
Premature infants below 30 weeks of gestation who receive Caffeine and Doxapram treatment
Group with no treatment
Premature infants below 30 weeks of gestation with no stimulating treatment


Ages Eligible for Study:   23 Weeks to 30 Weeks   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Preterm infants born below a gestational age of 30 weeks

Inclusion Criteria:

see above

Exclusion Criteria:

  • intraventricular hemorrhage
  • posthaemorrhagic hydrocephalus
  • cerebral infection
  • cerebral malformation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01344317

Medical University of Vienna, Department of Pediatrics and Adolescent Medicine, Neonatology
Vienna, Austria, 1090
Medical University of Vienna
Vienna, Austria, 1090
Sponsors and Collaborators
Medical University of Vienna
Principal Investigator: Manfred Weninger, MD, PhD Medical University of Vienna
  More Information

Responsible Party: Christine Czaba,, Medical University of Vienna Identifier: NCT01344317     History of Changes
Other Study ID Numbers: Nationalbankprojekt Nr.13660
Study First Received: April 27, 2011
Last Updated: October 30, 2015

Additional relevant MeSH terms:
Central Nervous System Stimulants
Physiological Effects of Drugs
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Purinergic P1 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents processed this record on May 25, 2017